Startups
Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening condit
Overview
Location
Germany, Rhineland-Palatinate, Mainz
Employees
11-50
Phone
+49 6131 5542860
Total raised
$22.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 12, 2024 | Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations | |
| Mar 7, 2024 | Europe Colorectal Cancer Screening and Diagnostic Market Analysis and Forecast 2023-2033, Featuring Key Players Epigenomics, Mainz Biomed and Novigenix | |
| Mar 5, 2024 | Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic | |
| Nov 13, 2023 | Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering | BERKELEY, Calif. and MAINZ, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced toda... |
| Nov 13, 2023 | Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering | |
| Jun 29, 2023 | Mainz Biomed Secures up to $50M in New Funding | |
| Jan 19, 2023 | Slone Partners Places Amy Levin as Vice President of Regulatory Affairs at Mainz Biomed | “Amy Levin is an extremely accomplished and highly respected regulatory affairs specialist with a stellar history of high performance across multiple organizations,” said Slone Partners President Tara Kochis. SOUTH RIDING, Va. (PRWEB) Janua... |
| Jan 29, 2022 | Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares | DGAP-News: Mainz BioMed N.V. / Key word(s): Capital Increase Mainz Biomed Announces the Closing of its $25.8 Million Public Follow-on Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares 28.01... |
| Dec 1, 2021 | Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods | FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Early onset colorectal cancer is currently on the rise [1], according to a new study [2] from the University of Colorado School of Medicine i... |
Show more
Reviews 0
FAQ about Mainz Biomed
How much funding has Mainz Biomed raised?
Mainz Biomed has raised $22.5M in total across 1 funding round.
What has the press written about Mainz Biomed?
Parsers VC has collected 12 articles mentioning Mainz Biomed, among them “Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations” (Mar 12, 2024) and “Europe Colorectal Cancer Screening and Diagnostic Market Analysis and Forecast 2023-2033, Featuring Key Players Epigenomics, Mainz Biomed and Novigenix” (Mar 7, 2024).
Is Mainz Biomed still active?
Yes, Mainz Biomed is active; its latest activity on Parsers VC dates from Dec 16, 2024.